Učitavanje...
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal α-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have...
Spremljeno u:
| Izdano u: | Orphanet J Rare Dis |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6162957/ https://ncbi.nlm.nih.gov/pubmed/30268124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0916-1 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|